Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure

Background & Aims This is a phase II multicentre study to investigate the efficacy and safety of avatrombopag (E5501), an investigational second-generation thrombopoietin receptor agonist, administered one week prior to elective procedures in patients with thrombocytopenia secondary to cirrhosis. Methods Adults with cirrhosis and platelet counts ⩾10 to ⩽58 × 109/L were randomized to placebo or avatrombopag in two sequential cohorts. Cohort A:...